Browse by Vaccine Type

This page shows data for Non-replicating viral vector vaccine type.
Total Entries Retrieved: 20
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10015 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA NA NA 2 doses 4 weeks apart Intramuscular NA NA NA NA NA Argentina, India, Morocco, Britain, Mexico, El Salvador, Dominican Republic AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://vk.ovg.ox.ac.uk/vk/covid-19-vaccines https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
10016 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA NA NA 2 doses 28 days apart Intramuscular NA NA NA US FDA NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10019 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved Janssen Pharmaceutical NA NA NA 2 doses 56 days apart Intramuscular NA NA NA US FDA NA NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://www.fda.gov/media/153439/download
10023 Gam-COVID-Vac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved Gamaleya Research Institute of Epidemiology and Microbiology NA Russia NA 2 doses 21 days apart Intramuscular NA rAd26-S, rAd5-S NA US FDA Health Ministry of the Russian Federation NA Sputnik-V 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10046 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved Janssen Vaccines & Prevention B.V. NA Leiden, Netherlands NA NA Intramuscular NA NA Recombinant replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding Spike protein antigen of the SARS-CoV-2 EMA NA NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf NA
10060 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Approved Janssen Pharmaceutical 2020 USA 18 years and above NA Intramuscular NA NA NA US FDA, WHO, Africa Regulatory Taskforce Endorsed, Caribbean Regulatory System Emergency Use Recommendation NA Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine, USA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine NA NCT04436276 https://clinicaltrials.gov/show/NCT04436276 NA
10153 AdCOVID COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Altimmune Inc. NA USA 18 - 55 years NA Intranasal NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10154 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 University Medical Center Hamburg-Eppendorf NA Germany 18 - 55 years NA Intramuscular NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10155 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Ludwig-Maximilians, University of Munich NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10158 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 ReiThera Srl 2021 Italy 18 - 85 years NA Intramuscular NA NA NA NA NA NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10180 iNCOVACC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 Bharat Biotech International Limited 2021 India 18 - 60 years 2 doses 28 days apart Intranasal NA Spike protein of SARS-CoV-2 virus NA NA NA NA BBV154 NA NA http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=51327 NA
10195 ChAdOx1 MERS (MERS002) MERS Respiratory MERS-CoV positive-sense, single-stranded RNA Non-replicating viral vector Phase 1 King Abdullah International Medical Research Center 2020 Saudi Arabia 18 - 50 years NA Intramuscular NA Eplication-deficient simian adenoviral vector expressing the spike protein of MERS Coronavirus NA NA University of Oxford NA NA NA NCT04170829 https://clinicaltrials.gov/ct2/show/NCT04170829?cond=MERS-CoV&phase=0123&draw=2&rank=3 NA
10200 Ad5-EBOV Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Non-replicating viral vector Phase 1 National Institute of Health 2010 USA 18 - 50 years NA Intramuscular NA Ebola virus envelope glycoprotein NA NA National Institute of Allergy and Infectious Diseases NA NA 27764560 NCT00374309 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ https://www.precisionvaccinations.com/vaccines/ad5-ebov-ebola-vaccine#:~:text=CanSinBio%20Ad5%2DEBOV%20is%20an,type%2D5%20vector%20immune%20response.
10280 AV-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Aivita Biomedical Inc. 2020 USA 18 years and above NA Intranasal GM-CSF Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA NA NCT05007496 https://clinicaltrials.gov/show/NCT04386252 https://clinicaltrials.gov/ct2/show/NCT05007496
10285 LV-SMENP COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Shenzhen Geno-Immune Medical Institute 2021 China 6 months and above NA Subcutaneous NA Covid-19 minigene SMENP and immune modulatory genes NA NA NA NA NA NA NCT04276896 https://clinicaltrials.gov/show/NCT04276896 NA
10292 BVRS-GamVac MERS Respiratory MERS-CoV positive-sense, single-stranded RNA Non-replicating viral vector Phase 2 Gamaleya Research Institute of Epidemiology and Microbiology 2021 Russia 18 - 55 years NA Intramuscular NA MERS CoV spike glycoprotein NA NA Health Ministry of the Russian Federation NA NA NA NCT04130594 https://clinicaltrials.gov/ct2/show/NCT04130594?cond=MERS-CoV&phase=0123&draw=2&rank=14 NA
10313 Convidecia COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 CanSino Biologics Inc. 2020 China 18 years and above Single dose Intramuscular NA NA NA NA NA NA PakVac, Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) NA NCT04526990 https://clinicaltrials.gov/show/NCT04526990 NA
10330 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 Janssen Vaccines & Prevention B.V. NA NA 18 years and above NA Intramuscular NA NA NA NA NA NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10348 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 3 ReiThera Srl NA Italy 18 years and above 2 doses 21 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04791423 https://clinicaltrials.gov/show/NCT04791423 NA
10376 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Non-replicating viral vector Phase 4 AstraZeneca plc, University of Oxford, Serum Institute of India 2020 UK 18 years and above 2 doses 4 to 12 weeks apart Intramuscular NA Spike protein of SARS-CoV-2 virus ChAdOx1 technology NA University of Oxford Japan, Korea, India AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://vk.ovg.ox.ac.uk/vk/covid-19-vaccines NA